114 related articles for article (PubMed ID: 10929879)
1. Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media.
Marshall SA; Kugler KC; Jones RN
Int J Antimicrob Agents; 2000 Aug; 15(4):291-7. PubMed ID: 10929879
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
3. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results.
King A; May J; Phillips I
J Antimicrob Chemother; 1998 Dec; 42(6):711-9. PubMed ID: 10052893
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
Jamjian C; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1997 Apr; 27(4):129-38. PubMed ID: 9154409
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Putnam SD; Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
[TBL] [Abstract][Full Text] [Related]
7. Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae.
Jorgensen JH; McElmeel ML
J Antimicrob Chemother; 1997 May; 39 Suppl A():69-73. PubMed ID: 9511067
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
9. Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group.
Fuchs P; Barry A; Brown S
Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):197-201. PubMed ID: 9665303
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
11. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
[TBL] [Abstract][Full Text] [Related]
12. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
Tenover FC; Baker CN
J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Ling TK; Fung KS; Cheng AF
Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae.
Izumikawa K; Hirakata Y; Yamaguchi T; Yoshida R; Tanaka H; Takemura H; Maesaki S; Tomono K; Kaku M; Izumikawa KI; Kamihira S; Kohno S
Antimicrob Agents Chemother; 1998 Mar; 42(3):698-9. PubMed ID: 9517955
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of an orally administered streptogramin (RPR 106,972) compared to quinupristin/dalfopristin and erythromycin.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):155-8. PubMed ID: 9105844
[TBL] [Abstract][Full Text] [Related]
16. A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae.
Mabe S; Champney WS
Curr Microbiol; 2005 Dec; 51(6):363-6. PubMed ID: 16252133
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres.
Barry AL; Fuchs PC; Brown SD
J Antimicrob Chemother; 1998 Nov; 42(5):651-5. PubMed ID: 9848451
[TBL] [Abstract][Full Text] [Related]
18. Activity of quinupristin-dalfopristin in invasive isolates of Streptococcus pneumoniae from Italy.
Pantosti A; D'Ambrosio F; Bordi E; Scotto D'Abusco A; Del Grosso M
Clin Microbiol Infect; 2001 Sep; 7(9):503-6. PubMed ID: 11678935
[TBL] [Abstract][Full Text] [Related]
19. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.
Barry AL; Fuchs PC; Brown SD
J Antimicrob Chemother; 1997 May; 39 Suppl A():87-92. PubMed ID: 9511070
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
